https://orcid.org/0000-0002-2381-9292
References
- Coates TD. Physiology and pathophysiology of iron in hemoglobin-associated diseases. Free Radic Biol Med. 2014;72:23–40.
- Borgna-Pignatti C, Cappellini MD, De Stefano P, et al. Survival and complications in thalassemia. Ann NY Acad Sci. 2005;1054:40–47.
- Cappellini MD, Cohen A, Porter J, et al. editors. Guidelines for the management of transfusion dependent thalassaemia (TDT). 3rd ed. Nicosia, Cyprus: Thalassaemia International Federation; 2014.
- Pennell DJ, Berdoukas V, Karagiorga M, et al. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood. 2006;107(9):3738–3744.
- Luangasanatip N, Chaiyakunapruk N, Upakdee N, et al. Iron-chelating therapies in a transfusion-dependent thalassaemia population in Thailand: a cost-effectiveness study. Clin Drug Investig. 2011;31(7):493–505.
- Hoffbrand AV. Deferiprone therapy for transfusional iron overload. Best Pract Res Clin Haematol. 2005;18(2):299–317.
- Olivieri NF, Sabouhanian A, Gallie BL. Single-center retrospective study of the effectiveness and toxicity of the oral iron chelating drugs deferiprone and deferasirox. PLoS One. 2019;14(2):e0211942.
- Viprakasit V, Nuchprayoon I, Chuansumrit A, et al. Deferiprone (GPO-L-ONE(®) ) monotherapy reduces iron overload in transfusion-dependent thalassemias: 1-year results from a multicenter prospective, single arm, open label, dose escalating phase III pediatric study (GPO-L-ONE; A001) from Thailand. Am J Hematol. 2013;88(4):251–260.
- Ceci A, Baiardi P, Felisi M, et al. The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients. Br J Haematol. 2002;118(1):330–336.
- Olivieri NF, Brittenham GM, Matsui D, et al. Iron-chelation therapy with oral deferiprone in patients with thalassemia major. N Engl J Med. 1995;332(14):918–922.
- Hoffbrand AV, Al-R F, Davis B, et al. Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients. Blood. 1998;91(1):295–300.
- Gomber S, Saxena R, Madan N. Comparative efficacy of desferrioxamine, deferiprone and in combination on iron chelation in thalassemic children. Indian Pediatr. 2004;41(1):21–27.
- Fischer R, Piga A, Santis V, et al. Large-scale study in Thalassemia using biomagnetic liver susceptometry. Biomag98: 11th International Conference Biomagnetism; 1998 Aug 28–Sep 2; Sendai, Japan: Tohoku University Press; 1998. p. 1–4.
- Fisher CA, Premawardhena A, de Silva S, et al. The molecular basis for the thalassaemias in Sri Lanka. Br J Haematol. 2003;121(4):662–671.
- Tantiworawit A, Charoenkwan P, Hantrakool S, et al. Iron overload in non-transfusion-dependent thalassemia: association with genotype and clinical risk factors. Int J Hematol. 2016;103(6):643–648.
- Taher A, Vichinsky E, Musallam K, et al. Biomagnetism. In: Weatherall D, editor. Guidelines for the management of non transfusion dependent Thalassaemia (NTDT). Nicosia, Cyprus: Thalassaemia International Federation. Thalassaemia International Federation; 2013. p. 1–4.
- Choudhry VP, Pati HP, Saxena A, et al. Deferiprone, efficacy and safety. Indian J Pediatr. 2004;71(3):213–216.
- Cohen AR, Galanello R, Piga A, et al. Safety profile of the oral iron chelator deferiprone: a multicentre study. Br J Haematol. 2000;108(2):305–312.
- Aydinok Y, Ulger Z, Nart D, et al. A randomized controlled 1-year study of daily Deferiprone plus twice weekly desferrioxamine compared with daily Deferiprone Monotherapy in patients with thalassemia major. Haematologica. 2007;92(12):1599–1606.
- Pepe A, Meloni A, Pistoia L, et al. MRI multicentre prospective survey in thalassaemia major patients treated with deferasirox versus deferiprone and desferrioxamine. Br J Haematol. 2018;183(5):783–795.
- Hassan MA, Tolba OA. Iron chelation monotherapy in transfusion-dependent beta-thalassemia major patients: a comparative study of deferasirox and deferoxamine. Electron Physician. 2016;8(5):2425–2431.
- Pennell DJ, Porter JB, Cappellini MD, et al. Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia major. Haematologica. 2012;97(6):842–848.
- Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood. 2006;107(9):3455–3462.
- Tricta F, Uetrecht J, Galanello R, et al. Deferiprone-induced agranulocytosis: 20 years of clinical observations. Am J Hematol. 2016;91(10):1026–1031.
- Cohen AR, Galanello R, Piga A, et al. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood. 2003;102(5):1583–1587.